<- Go Home
Oncorus, Inc.
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company develops ONCR-021 for the treatment of non-small cell lung cancer, renal cell carcinoma, melanoma, and anaplastic thyroid cancer; and ONCR-788 for the treatment of small cell lung cancer, neuroendocrine prostate, and other neuroendocrine cancers. The company was incorporated in 2015 and is based in Andover, Massachusetts. As of June 6, 2023, Oncorus, Inc. is in liquidation.
Market Cap
$3.3M
Volume
180.2K
Cash and Equivalents
$21.2M
EBITDA
-$69.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$0.47
52 Week Low
$0.01
Dividend
N/A
Price / Book Value
0.11
Price / Earnings
-0.04
Price / Tangible Book Value
0.11
Enterprise Value
$27.6M
Enterprise Value / EBITDA
-0.46
Operating Income
-$73.8M
Return on Equity
124.56%
Return on Assets
-32.24
Cash and Short Term Investments
$45.0M
Debt
$69.2M
Equity
$31.1M
Revenue
N/A
Unlevered FCF
-$52.3M
Sector
Biotechnology
Category
N/A